Though still in its infancy, the global precision medicine market already accounted for roughly $43.59 billion in 2016 and is estimated to reach $141.70 billion by 2026, according to a 2017 market intelligence report by BIS Research, titled "Global Precision Medicine Market- Analysis and Forecast, 2017-2026." Furthermore, in 2017, the FDA broke a record for the most new drug approvals, the majority of which were for personalized medicines.
But what does this mean for cold chain leaders? We asked the 2019 Cold Chain Spring speaker faculty about the challenges and innovative opportunities associated with the personalized medicine supply chain. Highlights include:
Please note: That all fields marked with an asterisk (*) are required.